Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the
neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated
Chinese adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. No formal
hypothesis testing will be done.
The China extension study will include participants previously enrolled in China in the
global study for MK-3475-585 (NCT03221426) plus those enrolled during the China extension
enrollment period. A total of approximately 120 Chinese participants will be enrolled.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.